肝癌组织中HOXA9 mRNA的表达及其临床意义

目的研究肝癌病例癌组织、癌旁组织及非癌肝组织中HOXA9 mRNA的表达及其临床意义.方法标本经10%中性福尔马林固定后常规制作石蜡包埋切片,HOXA9 mRNA行原位杂交检测.结果临床分析发现术后血清AFP值、AFU值、Glo值、PAB值及SHCSP阳性率均有明显减少.癌组织HOXA9mRNA阳性表达评分(1.94±1.69)明显低于非癌肝组织(3.17±1.70),两者有显著差异;癌旁组织HOXA9mRNA阳性表达评分(2.54±1.20)与非癌肝组织及癌组织无显著差异.癌组织、癌旁组织及非癌肝组织三者HOXA9mRNA阳性表达率(54.84%、76.92%、83.33%)无显著差异.除HCC中HOXA9RNA阳性表达评分(1.81±1.78)显著低于MHC(2.75±0.50)外,HOXA9mRNA表达阳性率及阳性评分与癌分化程度、AFP值、SHCSP是否阳性、AFU值、肝硬化有无、转移情况、有无癌栓、大体形态及肿块最大径等临床病理特征均无明显关系.结论本研究结果显示HOXA9mRNA可能与肝癌的发生有密切关系.临床上检测HOXA9mRNA的表达情况对肝癌的早期发现和早期诊断可能有较重要的临床意义,值得深入研究.

Expression of HOXA9 mRNA and its clinical significance in primary hepatocarcinoma

Objective: To study the expression of HOXA9 mRNA and its clinical significance in liver cancer tissues, paracancerous liver tissues and non -cancer liver tissues. Methods: HOXA9 mRNA was detected by in situ hybridization technique. The specimens were fixed by 10% neutral formalin and then routinely made into paraffin - embedded sections. Results: Clinical analysis showed significantly lower values of AFP, AFU, Glo and PAB and positiverate of SHCSP in postoperative patients. The scoring mean of HOXA9 nRNA expression in the cancer tissues ( 1.94 +i. 69) was significantly lower than that in the non - cancer liver tissues (3.17 + 1. 70). There was no significant differenee in scoring means of HOXA9 mRNA expression between the paracancerous tissues (2.54 ± 1.20) and non -cancerliver tissues. There was no significant difference in positive rate of HOXA9 mRNA expression among the cancer tissues,the paracancerous liver tissues and the non - cancer liver tissues (54.84%, 76.92% and 83.33% respectively). Apart from the scoring mean of HOXA9 mRNA expression being significantly lower in the HCC (1.81 ± 1.78) than in MHC (2.75 ± 0.50), no correlations were revealed between the positive rate, the scoring mean of HOXA9 mRNA andthe other clinical features. Conclusion: This study showed that the HOXA9 mRNA might be related to the carcinogenesis of hepatocarcinoma. The assays of HOXA9 mRNA expression might have important clinical values in theearly discovery and diagnosis of primary hepatocarcinoma.